Low density lipoprotein undergoes oxidative modification in vivo.

…, ME Rosenfeld, S Ylä-Herttuala… - Proceedings of the …, 1989 - National Acad Sciences
It has been proposed that low density lipoprotein (LDL) must undergo oxidative modification
before it can give rise to foam cells, the key component of the fatty streak lesion of …

Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine

S Ylä-Herttuala, TT Rissanen, I Vajanto… - Journal of the american …, 2007 - jacc.org
Members of the vascular endothelial growth factor (VEGF) family are among the most
powerful modulators of vascular biology. They regulate vasculogenesis, angiogenesis, and …

[HTML][HTML] Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union

S Ylä-Herttuala - Molecular Therapy, 2012 - cell.com
© The American Society of Gene & Cell Therapy editorial and predictability can be achieved
in the process of regulatory evaluation and approval. The Glybera saga also highlights …

History of gene therapy

T Wirth, N Parker, S Ylä-Herttuala - Gene, 2013 - Elsevier
Two decades after the initial gene therapy trials and more than 1700 approved clinical trials
worldwide we not only have gained much new information and knowledge regarding gene …

[HTML][HTML] Biology of vascular endothelial growth factors

H Roy, S Bhardwaj, S Ylä-Herttuala - FEBS letters, 2006 - Elsevier
Angiogenesis is the process by which new blood vessels are formed from existing vessels.
The vascular endothelial growth factors (VEGFs) are considered as key molecules in the …

Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth

…, M Egeblad, MJ Karkkainen, H Kubo, S Ylä-Herttuala… - Cancer research, 2001 - AACR
Many solid tumors produce vascular endothelial growth factor C (VEGF-C), and its receptor,
VEGFR-3, is expressed in tumor blood vessels. To study the role of VEGF-C in tumorigenesis…

Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3

…, DG Jackson, H Kubo, SI Nishikawa, S Ylä-Herttuala… - Nature medicine, 2001 - nature.com
The lymphatic vasculature transports extravasated tissue fluid, macromolecules and cells
back into the blood circulation. Recent reports have focused on the molecular mechanisms …

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation

…, P Laakkonen, G Christofori, S Ylä-Herttuala… - Nature, 2008 - nature.com
Angiogenesis, the growth of new blood vessels from pre-existing vasculature, is a key
process in several pathological conditions, including tumour growth and age-related macular …

[HTML][HTML] Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox‐1 homeobox transcription factor

…, DN Finegold, D Kerjaschki, S YläHerttuala… - The EMBO …, 2002 - embopress.org
Lymphatic vessels are essential for fluid homeostasis, immune surveillance and fat adsorption,
and also serve as a major route for tumor metastasis in many types of cancer. We found …

Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis …

…, MS Nieminen, M Laakso, S Ylä-Herttuala - Circulation, 2003 - Am Heart Assoc
Background— Catheter-based intracoronary vascular endothelial growth factor (VEGF) gene
transfer is a potential treatment for coronary heart disease. However, only limited data are …